BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

Dr. Kirk Shepard (Chief Medical Officer) detailed a pivotal change to the Phase III VERSATILE-003 study design: “we adopted an amendment to our VERSATILE-003 trial, revising the design to incorporate ...

PDS Biotechnology Corp (PDSB) progresses in clinical trials and patent protection, but faces financial hurdles and competitive pressures.

Net Loss -- $7.3 million, or $0.13 per basic and diluted share, compared to $8.5 million, or $0.21 per basic and diluted ...

An evidence gap persists in BCG-unresponsive NMIBC because pivotal approvals rely on single-arm studies, making indirect ...

Operator: Greetings, and welcome to the PDS Biotech First Quarter 2026 Earnings Conference Call. [Operator Instructions] It ...

WhiteFiber, Inc. ("WhiteFiber" or the "Company"), a leading provider of AI infrastructure and high-performance computing solutions, today announced that it has entered into a five-year agreement to ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending ...

Fulgent Genetics, Inc. ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its ...

RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 9:00 AM EDTCompany ParticipantsAndrew Peters - Senior ...

Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.